Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON
Related Posts
Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S,[...]
Teysir J, Lloyd MR, Alkassis S, Callahan RD, Fairley R, Wander SA, Bardia A, Jhaveri KL. After a CDK4/6 Inhibitor: State of the Art in[...]
Britten K, Bardia A, McAndrew N. Role of immunotherapy in early breast cancer: past, present, and future. Target Oncol. 2025 Jun 20. doi: 10.1007/s11523-025-01157-1. Epub[...]